NCT01609205View on ClinicalTrials.gov

Doppler Evaluation in RA Patients After Adalimumab.

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Adalimumab

Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD

Trial Locations (2)

Unknown

Linköping University Hospital, Linköping

171 76

The karolinska Institute, Stockholm

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Hamed Rezaei

OTHER